Roche |位置，政策和下载

位置，政策和下载

PDF"],["2022/11","Six bold actions for regulatory reform (EU)","Position\t","PDF"],["2022/11\t","Roche’s Position on Access to & Use of Real World Data\t","Position","PDF"],["2022/10","Roche FAQ Clinical Research","FAQs","PDF"],["2022/07\t","Half-Year Report 2022\t","Brochure","PDF"],["2022/07\t","Roche position on incentivising the development and appropriate use of new antibiotics\t","Policy","PDF"],["2022/06\t","EFPIA Disclosure Code Self-Certification Scheme\t","Position\t","PDF"],["2022/05\t","Responsible Sharing of Scientifically Credible Information on the portal\t","Position\t","PDF"],["2022/05\t","Pre-Approval Access to Investigational Medicinal Products\t","Position\t","PDF"],["2022/02\t","Finance Report 2021\t","Brochure\t","PDF"],["2022/02\t","Annual Report 2021\t","Brochure\t","PDF"],["2021/12\t","Employment Policy (German)\t","Policy","PDF"],["2021/12\t","Employment Policy (Spanish)\t","Policy","PDF"],["2021/12\t","Employment Policy (English)\t","Policy","PDF"],["2021/12\t","Employment Policy (Chinese)\t","Policy","PDF"],["2021/12\t","Employment Policy (French)\t","Policy","PDF"],["2021/12\t","Employment Policy (Italian)\t","Policy","PDF"],["2021/11\t","Roche Group Code of Conduct - Addendum for France (French)\t","Policy","PDF"],["2021/11\t","Roche Group Code of Conduct - Addendum for France (English)\t","Policy","PDF"],["2021/09\t","Waste Management and Circular Economy\t","Position","PDF"],["2021/07\t","Energy Conservation\t","Position","PDF"],["2021/07\t","Prevention of Misuse of Biological Materials and Toxins for Biowarfare\t","Position","PDF"],["2021/07\t","Water","Position","PDF"],["2021/07\t","Half-Year Report 2021\t","Brochure","PDF"],["2021/06\t","EFPIA Disclosure Code Self-Certification Scheme\t","Policy","PDF"],["2021/06\t","Roche Position on TRIPS and the Doha Declaration\t","Position\t","PDF"],["2021/06\t","Roche Position on Enabling Access through Collaboration\t","Position\t","PDF"],["2021/05\t","Climate Change Risk Management\t","Fact Sheet\t","PDF"],["2021/05\t","Policy on Safety, Security, Health and Environmental Protection\t","Policy","PDF"],["2021/05\t","Roche’s Approach to Tax – General Description and Principles\t","Principles\t","PDF"],["2021/05\t","Roche's Position on Partnering with Patient Communities\t","Position","PDF"],["2021/02\t","Finance Report 2020\t","Brochure\t","PDF"],["2021/02\t","Annual Report 2020\t","Brochure\t","PDF"],["2021/02\t","Roche Position on Health Technology Assessment\t","Position","PDF"],["2020/07\t","Half-Year Report 2020\t","Brochure\t","PDF"],["2020/06\t","EFPIA Disclosure Code Self-Certification Scheme\t","Policy","PDF"],["2020/04\t","Biodiversity","Position","PDF"],["2020/04\t","Biotechnology - Safety Health and Environmental Aspects\t","Position","PDF"],["2020/04\t","Clinical Research\t","Position","PDF"],["2020/04\t","Counterfeiting","Position","PDF"],["2020/04\t","Greenhouse gases / Climate Change\t","Position","PDF"],["2020/04\t","Position on Human Specimen Resources (Biobanks)\t","Position","PDF"],["2020/04\t","Human Stem Cells\t","Position","PDF"],["2020/04\t","Landfills / Contaminated Soil\t","Position","PDF"],["2020/04\t","Personalised Healthcare\t","Position","PDF"],["2020/04\t","Pharmaceuticals in the Environment\t","Position","PDF"],["2020/04\t","Pricing","Position","PDF"],["2020/04\t","R&D for Neglected Tropical Disease\t","Position","PDF"],["2020/04\t","Similar Biotherapeutic Products - Biosimilars\t","Position","PDF"],["2020/04\t","Pollution Prevention and Reduction\t","Position","PDF"],["2020/04\t","Product Stewardship\t","Position","PDF"],["2020/04\t","Safety, Security, Health and Environmental Protection (SHE) in the supply chain\t","Position","PDF"],["2020/04\t","Human Rights\t","Position","PDF"],["2020/04\t","Human Genetic and Genomic Research\t","Position","PDF"],["2022/05\t","Animal Research at Roche\t","Position","PDF"],["2020/02\t","Roche Group Code of Conduct (Chinese)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (German)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Spanish)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (French)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct - Addendum for France (French)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Italian)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Portuguese - Brasil)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Japanese)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Portuguese)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Russian)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (Turkish)\t","Policy","PDF"],["2020/02\t","Roche Group Code of Conduct (English)\t","Policy","PDF"],["2020/01\t","Roche in Brief 2019\t","Brochure","PDF"],["2020/01\t","Finance Report 2019\t","Brochure","PDF"],["2020/01\t","Annual Report 2019\t","Brochure","PDF"],["2019/12\t","Supplier Code of Conduct (French)\t","Guidelines","PDF"],["2019/12\t","Supplier Code of Conduct (English)\t","Guidelines","PDF"],["2019/07\t","Half-Year Report 2019\t","Brochure","PDF"],["2019/07\t","EFPIA Disclosure Code Self-Certification Scheme\t","Policy","PDF"],["2019/02\t","SHE Guidelines\t","Guidelines","PDF"],["2019/01\t","Roche in Brief 2018\t","Brochure","PDF"],["2019/01\t","Finance Report 2018\t","Brochure","PDF"],["2019/01\t","Annual Report 2018\t","Brochure","PDF"],["2019/01\t","Compliance","Fact Sheet\t","PDF"],["2019/01\t","Roche illness rate and occupational illnesses\t","Fact Sheet\t","PDF"],["2019/01\t","Roche accident rate\t","Fact Sheet\t","PDF"],["2019/01\t","Supporting Biodiversity\t","Fact Sheet\t","PDF"],["2019/01\t","Waste Management\t","Fact Sheet\t","PDF"],["2019/01\t","Use of water\t","Fact Sheet\t","PDF"],["2019/01\t","Emissions to water\t","Fact Sheet\t","PDF"],["2019/01\t","Other emissions to air\t","Fact Sheet\t","PDF"],["2019/01\t","Greenhouse Gas Emissions\t","Fact Sheet\t","PDF"],["2019/01\t","Energy Consumption\t","Fact Sheet\t","PDF"],["2019/01\t","Eco-balance\t","Fact Sheet\t","PDF"],["2019/01\t","SHE expenditures\t","Fact Sheet\t","PDF"],["2019/01\t","Materiality","Fact Sheet\t","PDF"],["2018/12\t","Roche Directive Collaborating with Patient Groups and Patients\t","Guidelines","PDF"],["2018/10\t","Intellectual Property, Fueling Innovation & Advancing Healthcare\t","Position","PDF"],["2018/10\t","Certificate on Roche's Sustainability Commitments, Initiatives and Performance\t","Fact Sheet\t","PDF"],["2018/08\t","Employment Policy\t","Policy","PDF"],["2018/07\t","Half-Year Report 2018\t","Brochure","PDF"],["2018/06","Group Business Continuity Management Policy\t","Policy","PDF"],["2018/05\t","Working with Government Officials\t","Guidelines","PDF"],["2018/05\t","Philanthropic Donations and Non-commercial Sponsorship\t","Policy","PDF"],["2018/03\t","Organisationsreglement\t","Policy","PDF"],["2018/03\t","Bylaws","Policy","PDF"],["2018/02\t","Transport","Fact Sheet\t","PDF"],["2018/02\t","Roche in Brief 2017\t","Brochure","PDF"],["2018/02\t","Finance Report 2017\t","Brochure","PDF"],["2018/02\t","Annual Report 2017\t","Brochure","PDF"],["2017/11\t","Roche Policy on sharing of clinical study information\t","Policy","PDF"],["2017/06\t","EFPIA Disclosure Code Self-Certification Scheme\t","Policy","PDF"],["2017/05\t","Benefits - Switzerland\t","Brochure","PDF"],["2017/02\t","Full Year 2016 Presentation without appendix\t","Brochure","PDF"],["2017/02\t","Finance Report 2016\t","Brochure","PDF"],["2016/06\t","Counterfeit Medicinal products\t","FAQs","PDF"],["2016/03\t","SHE Organization Chart\t","Fact Sheet\t","PDF"],["2016/03\t","Behaviour in Competition\t","Guidelines","PDF"],["2016/03\t","Behaviour in Competition (German)\t","Guidelines","PDF"],["2016/03\t","Articles of Incorporation\t","Policy","PDF"],["2015/09\t","Group Insider Policy\t","Policy","PDF"],["2015/05\t","Roche Specimen Repositories\t","FAQs\t","PDF"],["2015/02\t","Directive K18 - Annex 2 (Lighting)\t","Brochure","PDF"],["2014/10\t","Directive K1 - Annex 5 (Mental Health Protection)\t","Policy","PDF"],["2014/10\t","Directive K1 - Occupational Health\t","Policy","PDF"],["2022/05\t","Behaviour in Business (English)\t","Guidelines","PDF"],["2022/05\t","Behaviour in Business (German)\t","Guidelines","PDF"],["2022/05\t","Behaviour in Business (French)\t","Guidelines","PDF"],["2014/03\t","Minutes of the 96th Annual General Meeting of the Shareholders of ROCHE HOLDING LTD\t","Fact Sheet\t","PDF"],["2022/06\t","Continued Access to Investigational Medicines\t","Policy","PDF"],["2012/03\t","Risk Management\t","Policy","PDF"],["2009/10\t","Memberships and International CR Recommendations\t","Fact Sheet\t","PDF"]]" slot="left" uid="b8e9ca7c-6874-4925-81c3-6fed934ba18b" id="b8e9ca7c-6874-4925-81c3-6fed934ba18b" storyid="77463498" class="sc-roche-responsive-table-h hydrated">

日期

2022/11

2022/10

2022/07

2022/06

2022/05

2022/02

2021/12

2021/11

2021/09

2021/07

2021/06

2021/05

2021/02

2020/07

2020/06

2020/04

2022/05

2020/02

2020/01

2019/12

2019/07

2019/02

2019/01

2018/12

2018/10

2018/08

2018/07

2018/06

2018/05

2018/03

2018/02

2017/11

2017/06

2017/05

2017/02

2016/06

2016/03

2015/09

2015/05

2015/02

2014/10

2022/05

2014/03

2022/06

2012/03

2009/10

标题

纳米技术

监管改革的六项大胆行动(欧盟)

罗氏在获取和使用真实世界数据方面的立场

Roche FAQ临床研究

2022年半年报告

罗氏在鼓励开发和适当使用新抗生素方面的立场

EFPIA披露代码自我认证计划

在门户网站上负责地分享科学可信的信息

临床试验药品的预批准获取

2021年财务报告

2021年年报

就业政策(德语)

就业政策(西班牙语)

就业政策(中文)

就业政策(法语)

就业政策(意大利语)

罗氏集团行为准则-法国版附录(法文)

罗氏集团行为准则-法国版附录(英文)

废物管理与循环经济

节能

防止在生物战中滥用生物材料和毒素

水

2021年半年度报告

EFPIA披露代码自我认证计划

罗氏对与贸易有关的知识产权问题和多哈宣言的立场

罗氏关于通过协作实现访问的立场

气候变化风险管理

安全、保障、健康和环境保护政策

罗氏的税收方法——概述和原则

罗氏与患者社区合作的立场爱游戏ayx信誉

2020年财务报告

2020年年报

罗氏关于卫生技术评估的立场

2020年半年度报告

EFPIA披露代码自我认证计划

生物多样性

生物技术-安全、健康和环境问题

临床研究

伪造

温室气体/气候变化

人类标本资源(生物库)

人类干细胞

堆填区/污染土壤

个性化医疗

环境中的药物

定价

被忽视热带病的研发

类似生物治疗产品-生物仿制药

预防及减少污染

产品管理

供应链中的安全、保障、健康和环境保护(SHE)

人权

人类遗传与基因组研究“，

罗氏动物研究

罗氏集团行为准则(中文)

罗氏集团行为准则(德文)

罗氏集团行为准则(西班牙语)

罗氏集团行为准则(法文)

罗氏集团行为准则-法国版附录(法文)

罗氏集团行为准则(意大利语)

罗氏集团行为准则(葡萄牙语-巴西语)

罗氏集团行为准则(日语)

罗氏集团行为准则(葡萄牙语)

罗氏集团行为准则(俄语)

罗氏集团行为准则(土耳其语)

罗氏集团行为准则(英文)

罗氏2019简介

2019年财务报告

2019年年报

供应商行为守则(法文)

供应商行为准则(英文)

2019年半年度报告

EFPIA披露代码自我认证计划

她的指导方针

罗氏2018简介

2018年财务报告

2018年年报

合规

罗氏病率和职业病

罗氏事故率

支持生物多样性

废物管理

水的使用

排放到水中

其他空气排放物

温室气体排放

能源消耗

Eco-balance

她支出

物质

罗氏指令与患者群体和患者合作

知识产权，促进创新和推进医疗保健

罗氏可持续发展承诺、倡议和表现证书爱游戏体育博彩

就业政策

2018年半年度报告

集团业务连续性管理政策

与政府官员合作

慈善捐款和非商业赞助

Organisationsreglement

规章制度

运输

罗氏2017简介

2017年财务报告

2017年年报

罗氏临床研究信息共享政策

EFPIA披露代码自我认证计划

福利——瑞士

2016年全年报告，无附录

2016年财务报告

假冒药品

SHE组织结构图

竞争行为

竞争行为(德语)

公司章程

集团内部政策

罗氏标本库

指示K18 -附件2(照明)

指令K1 -附件5(精神健康保护)

指令K1——职业健康

商业行为(英文)

商业行为(德语)

商业行为(法语)

罗氏控股有限公司第96届年度股东大会记录

继续获得临床试验药物

风险管理

会员及国际CR推荐

类型

位置

常见问题

宣传册

政策

位置

宣传册

政策

位置

宣传册

政策

位置

简报

政策

原则

位置

宣传册

位置

宣传册

政策

位置

政策

宣传册

的指导方针

宣传册

政策

的指导方针

宣传册

简报

的指导方针

位置

简报

政策

宣传册

政策

的指导方针

政策

简报

宣传册

政策

宣传册

常见问题

简报

的指导方针

政策

常见问题

宣传册

政策

的指导方针

简报

政策

简报

下载

PDF

爱游戏体育博彩可持续发展下载中心

爱游戏ayx官方

爱游戏体育博彩可持续发展下载中心

发现更多的